Canadian Science Publishing (CSP) is pleased to announce that the Journal of Psychiatry and Neuroscience (JPN) is now officially part of our journal portfolio, following the completed acquisition from CMA Impact Inc. on September 2, 2025.
This marks a significant milestone for CSP, as JPN becomes the 23rd journal in our portfolio and our first in the fields of psychiatry and neuroscience. As the official journal of the Canadian College of Neuropsychopharmacology, JPN holds a leading position in its field. We’re proud to bring this respected title into our growing suite of journals and to support its continued contribution to high-quality, impactful research. As part of CSP, JPN will benefit from our not-for-profit, researcher-led approach and our strong commitment to editorial independence and publishing excellence.
For our community, this means new opportunities to engage with leading-edge work at the intersection of neuroscience and mental health, guided by a trusted editorial board that remains fully independent and committed to scholarly excellence. We look forward to connecting with new readers, authors, and reviewers in this space and to helping JPN continue to thrive in its new home. To stay connected with JPN, and any other journals in our suite, please click here.
About Canadian Science Publishing
Canadian Science Publishing (CSP) is committed to enhancing the reach, rigour, and relevance of science so that people can find, trust, and use it. Featuring content from a global community of researchers, CSP is an independent not-for-profit publisher led by a dedicated team of researchers who are committed to advancing excellence in scientific journal publishing. Visit us at www.cdnsciencepub.com.